myBiometry is a Boston-based company focused on improving asthma management through innovative technology. The company's primary offering, Mya, is a comprehensive asthma solution that combines home-based diagnostics, digital health, and a care team to identify patients at risk and proactively intervene to prevent asthma attacks. At the core of Mya is a patented sensor and device that measures fractional exhaled nitric oxide (FeNO) in breath, a biomarker of airway inflammation. This technology allows users to detect changes in their condition up to 20 days before symptoms or attacks occur, enabling early intervention.
The Mya system includes a device that collects FeNO measurements and indoor environmental data of known asthma triggers. Users perform a daily test by exhaling into the device, with results immediately displayed on a connected app. The app also tracks symptom scores, asthma control, and exposure to indoor and outdoor environmental triggers. myBiometry's algorithms analyze this data to provide personalized, actionable insights. Interventions are delivered proactively through the app or via a care team consisting of certified asthma educators, nurses, and physicians.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.